Treatment outcomes and considerations for topical immunotherapy in patients with alopecia totalis and alopecia universalis [PDF]
Frontiers in MedicineBackgroundAlopecia areata (AA) is a chronic immune-mediated disorder causing non-scarring hair loss. Severe forms like alopecia totalis (AT) and alopecia universalis (AU) pose therapeutic difficult situations.
Taiyo Hitaka +6 more
doaj +3 more sources
Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis [PDF]
CureusObjectives Tofacitinib, an effective Janus kinase inhibitor (JAKi), has gained increasing interest in recent years for the management of refractory alopecia areata (AA). One of the most prevalent autoimmune diseases is AA, a kind of non-scarring alopecia.
S. Tirmizi +3 more
semanticscholar +4 more sources
Clinical case of alopecia totalis in pediatric practice [PDF]
Сучасна педіатрія: Україна, 2023 Alopecia (baldness) is a pathological hair loss. A chronic relapsing course leads to a violation of the emotional sphere of the child, worsens the quality of life.
O.А. Stroi +4 more
doaj +3 more sources
A case of unusual comedogenesis in alopecia totalis
Indian Dermatology Online Journal, 2022 A 19‐year‐old male with a 3‐year history of alopecia totalis came to our department with multiple asymptomatic blackhead‐like lesions all over the bald scalp for 3 months.
Balkrishna P Nikam +3 more
doaj +4 more sources
A retrospective study on the clinical characteristics and prognosis of alopecia totalis and universalis: An update on prognosis [PDF]
Journal of dermatology (Print), 2023 Alopecia totalis (AT) and alopecia universalis (AU) is known to have a poor prognosis with high relapse rate, and treatment failure is observed in most patients, regardless of the type of therapy.
Sangmin Choi +4 more
semanticscholar +2 more sources
Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population [PDF]
JAMA dermatology, 2023 Key Points Question What is the contemporary prevalence and incidence of alopecia areata (AA), alopecia totalis, and alopecia universalis in the US? Findings In this cohort study of a nationwide US employer-sponsored insurance population, AA prevalence ...
A. Mostaghimi +7 more
semanticscholar +2 more sources
Treatment Response to Diphenylcyclopropenone in Patients with Alopecia Totalis/Universalis
International Journal of Trichology, 2023 Introduction: Alopecia totalis (AT) and Alopecia universalis (AU) are forms of Alopecia areata (AA) which represent the strongest predictor of poor prognosis since spontaneous regrowth is
S. Varghese +3 more
semanticscholar +2 more sources
A Case of Azathioprine Induced Severe Myelosuppression and Alopecia Totalis in IgA Nephropathy [PDF]
Childhood Kidney Diseases, 2017 Azathioprine is commonly used as immunosuppressive therapy for various inflammatory diseases including chronic glomerulonephritis. Myelosuppression is a common side effect of azathioprine, resulting in the need for dose reduction.
Jae Choon Kim +6 more
doaj +3 more sources
Effective management Alopecia totalis by Ayurveda – A case report
Journal of Ayurveda and Integrative Medicine, 2023 Alopecia areata (AA) is a T-cell-mediated autoimmune illness characterized by intermittent, non-scarring hair loss, Alopecia totalis(AT) is a type of AA characterized by total hair loss on the face and scalp.
Shivanand B. Patil +2 more
doaj +2 more sources
Treatment of alopecia totalis/universalis/focalis with vitamin D and analogs: Three case reports and a literature review [PDF]
, 2021 BACKGROUND: Alopecia areata (AA) is an inflammatory disease with autoimmune, environmental, and inherited components directed at the hair follicle, either limited to patchy hair loss over the scalp (Focalis, AF), total loss of scalp hair (Totalis, AT ...
Alexopoulos, Alexios +4 more
core +3 more sources